This review highlights the development of novel oral anticoagulants targeting factor IIa and Xa as potential alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Should not yet change anticoagulation practice; leaves open future alternatives from ongoing phase III trials.
Sobieraj‐Teague et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: